PubMed Health⌕ Search

PubMed · 12662823

Soft vector quantization and the EM algorithm.

Abstract

The relation between hard c-means (HCM), fuzzy c-means (FCM), fuzzy learning vector quantization (FLVQ), soft competition scheme (SCS) of [Yair et al. (1992)] and probabilistic Gaussian mixtures (GM) have been pointed out recently by [Bezdek and Pal (1995)]. We extend this relation to their training, showing that learning rules by these models to estimate the cluster centers can be seen as approximations to the expectation-maximization (EM) method as applied to Gaussian mixtures. HCM and unsupervised, LVQ use 1-of-c type competition. In FCM and FLVQ, membership is the -2/(m-1)th power of the distance. In SCS and GM, Gaussian function is used. If the Gaussian membership function is used, the weighted within-groups sum of squared errors used as the fuzzy objective function corresponds to the maximum likelihood estimate in Gaussian mixtures with equal priors and covariances. The fuzzy clustering method named fuzzy c-means alternating optimization procedure (FCM-AO) proposed to optimize the former is then equivalent to batch EM and SCS's update rule is a variant of the online version of EM. The advantages of the probabilistic framework are: (i) we no longer have spurious spread parameters that needs fine tuning as m in fuzzy vector quantization or beta in SCS; instead we have a variance term that has a sound interpretation and that can be estimated from the sample; (ii) EM guarantees that the likelihood does not decrease, thus it converges to the nearest local optimum; (iii) EM also allows us to estimate the underlying distance norm and the cluster priors which we could not with the other approaches. We compare Gaussian mixtures trained with EM with LVQ (HCM), SCS and FLVQ on the IRIS dataset and see that it is more accurate due to its being able to take into account the covariance information. We finally note that vector quantization is generally an intermediate step before finding a final output for which supervision may be possible. Thus, instead of an uncoupled approach where an unsupervised method is used first to find the cluster parameters followed by supervised training of the mapping based on the memberships, we advocate a coupled approach where the cluster parameters and mapping are trained supervised in a coupled way. The uncoupled approach ignores the error at the outputs which may not be ideal.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ethem Alpaydin. 1998. Soft vector quantization and the EM algorithm.. https://doi.org/10.1016/s0893-6080(97)00147-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗